Recro Pharma Inc. (NASDAQ:REPH) shares were down 5.6% during trading on Tuesday . The company traded as low as $8.00 and last traded at $8.30, with a volume of 122,096 shares trading hands. The stock had previously closed at $8.79.

A number of research analysts have recently commented on REPH shares. Brean Capital reaffirmed a “buy” rating and set a $28.00 price target on shares of Recro Pharma in a research report on Friday, May 13th. HC Wainwright reaffirmed a “buy” rating on shares of Recro Pharma in a research report on Monday, July 18th. Finally, Zacks Investment Research raised Recro Pharma from a “sell” rating to a “hold” rating in a report on Thursday, July 14th.

The company’s market cap is $83.79 million. The stock has a 50 day moving average price of $8.60 and a 200 day moving average price of $7.41.

Recro Pharma (NASDAQ:REPH) last announced its quarterly earnings data on Thursday, August 11th. The specialty pharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.78) by $0.05. The business earned $17.30 million during the quarter, compared to analyst estimates of $18.70 million. Equities analysts expect that Recro Pharma Inc. will post ($3.44) earnings per share for the current fiscal year.

In other Recro Pharma news, major shareholder Scp Vitalife Partners (Israel) sold 6,260 shares of Recro Pharma stock in a transaction on Friday, May 20th. The stock was sold at an average price of $6.46, for a total value of $40,439.60. Following the completion of the sale, the insider now owns 783,642 shares of the company’s stock, valued at approximately $5,062,327.32. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Healthcare Master Fun Broadfin bought 390,000 shares of Recro Pharma stock in a transaction on Tuesday, August 16th. The stock was acquired at an average cost of $7.50 per share, with a total value of $2,925,000.00. The disclosure for this purchase can be found here.

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery. The Company’s lead product is an intranasal formulation of Dexmedetomidine (Dex). Its product candidates for pain indications include: Dex-IN, Dex-SL and Fadolmidine (Fado).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.